Phase 2
Completed N=13
Acetyl-L-Carnitine in the Treatment of Septic Shock
Source: ClinicalTrials.gov NCT00592488 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jun 2011
Primary outcomePrimary: Mean Arterial Blood Pressure — 60; 60 mm Hg
Summary
This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Arterial Blood Pressure |
60; 60 | — |
| SECONDARY Vasopressor Dose |
-1.4; -4.8 | — |
| SECONDARY Serum Lactate |
2.1; 2.0 | — |
Eligibility Criteria
Inclusion Criteria
- documented or presumed infection
- shock requiring vasopressors
Exclusion Criteria
- dialysis
- hepatic failure
- seizures
Data sourced from ClinicalTrials.gov (NCT00592488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.